ProPhase Labs, Inc. Stock News

UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results...

Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, July 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and con...

Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") today announced the closing of a private placement financing with two investors for $3 million in senior secured convertible notes with accompanying warrants to purchase shares of c...

UNIONDALE, NY, July 21, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that its Board of Directors has unanimously authorized the Company's executive team to explore a potential reverse merger transaction with a digital asset-focused operating company to supplement its ...

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement s...

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States

UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-SmartTM molecular test for esophageal disease. The advisory board wil...

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning everyone. Welcome to today's presentation.